Mode of action for short-term benefits of staph toxoid in FM/CFS

[Guest guest]

What does this reference tell us about the mode of action for the

staph toxoid, and in turn about the disease process in which it

provides temporary relief?

Eur J Clin Microbiol Infect Dis. 2004 Feb;23(2):98-105. Epub 2004

Jan 20.

Immune modulation with a staphylococcal preparation in

fibromyalgia/chronic fatigue syndrome: relation between antibody

levels and clinical improvement.

Zachrisson O, Colque-Navarro P, Gottfries CG, Regland B, Mollby R.

Institute of Clinical Neuroscience, SU/Molndal, 43180 Molndal,

Sweden. olof.zachrisson@...

The aims of this study were to evaluate the serological response to

treatment with staphylococcal vaccine in fibromyalgia/chronic

fatigue syndrome patients and to explore the relationship between

serological response and clinical effect.

Twenty-eight patients, half of whom served as controls, were

recruited from a 6-month randomised trial in which repeated

administration of the staphylococcal toxoid vaccine Staphypan Berna

(Berna Biotech, Switzerland) was tested against placebo. Antibody

status against extracellular toxins/enzymes, cell-wall components,

and enterotoxins was evaluated at baseline and at endpoint.

The clinical response to treatment was recorded in rating scales. In

the group receiving active treatment, significant serological

changes were recorded, whereas no significant changes were found in

controls.

Treatment led to a significantly increased capacity of serum to

neutralise alpha-toxin and a significant increase in serum IgG to

alpha-toxin and lipase. Furthermore, the increase in these

parameters combined paralleled the improvement in clinical outcome.

Thus, the greater the serological response, the greater was the

clinical effect. In conclusion, this explorative study has shown

that repeated administration of the Staphypan Berna vaccine in

patients with fibromyalgia/chronic fatigue syndrome causes a

serological response to several staphylococcal antigens,

particularly to certain extracellular toxins and enzymes. The

results further show that this response is related to the clinical

outcome of treatment.

Publication Types:

Clinical Trial

Randomized Controlled Trial

PMID: 14735403 [PubMed - indexed for MEDLINE]

> > >

> > > I did get something from a local allergy specialist called a

> staph

> > > toxoid vaccine which I found brilliant- yet it wore off

> > > quick.Apparently there's a couple of different versions of

this

> > and

> > > I think it's big vetenary medicine more than human medicine.

> > There's

> > > a company in switzerland BERN pharmaceuticals that make this-

I

> > > think.It's also sometyhing that comes in different grades or

> > > strengths again the one I got isn't necessarily the one that

> they

> > > talk about in the study.

> > > Actually to give you an idea of the vaccine I put subdermally-

> > while

> > > flaring/feeling miserable it stopped me almost after 10

> minutes.Th

> > > effect sort of lasts the day and the preceeding days aren't as

> bad.

> > > More later I'm out the door.

> > > tony

> > >